Palatin Technologies, Inc. (PTN)
Pre-market:
| Previous close | 1.8400 |
| Open | 1.8400 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 3200 |
| Day's range | 1.7000 - 1.9000 |
| 52-week range | 1.4300 - 5.6500 |
| Volume | |
| Avg. volume | 700,080 |
| Market cap | 27.755M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9800 |
| Earnings date | 14 May 2024 - 20 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.33 |
Insider Monkey10 Micro-Cap Healthcare Stocks Insiders Are Buying
In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]
ZacksPalatin (PTN) Up 15% on Results From Dry Eye Disease Study
A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.
PR NewswirePalatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 pivotal clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery (ASCRS).
